Processes for converting a hydrocarbon reactant into an alcohol compound and/or a carbonyl compound are disclosed in which the hydrocarbon reactant and either a supported chromium (VI) catalyst or a supported chromium (II) catalyst are contacted, optionally with UV-visible light irradiation, followed by exposure to an oxidizing atmosphere and then hydrolysis to form a reaction product containing the alcohol compound and/or the carbonyl compound. The presence of oxygen significant increases the amount of alcohol/carbonyl product formed, as well as the formation of oxygenated dimers and trimers of certain hydrocarbon reactants.

The present invention relates to compounds of formula (I): ##STR00001##
or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R.sup.2a, R.sup.2b, R.sup.2c, R.sup.5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.

The present invention relates to process for the preparation of cannabidiol (A) from the coupling of (D) and (E) through the intermediates (C) and (D) starting from compound (B). The invention further relates to the novel compounds (B), (C), (D) and (E) and reagents used in this process. More specifically, this invention provides the manufacturing of Cannabidiol (A) in milligram to gram or kilogram scale.

##STR00001##

Described herein is a method of using cyclic oxy ether compounds of formula ##STR00001##
in a form of any one of its stereoisomers or a mixture thereof, where the dotted line represents a carbon-carbon single or double bond; p represents 0 to 3; n represents 0 to 2; R represents, independently from each other hydrogen, a C.sub.1-C.sub.6 alkyl or C.sub.2-C.sub.6 alkenyl group each optionally substituted by an ester group; and R.sup.1 represents, independently from each other, a hydrogen atom or a C.sub.1-C.sub.3 alkyl group, the method including using the compound of formula (I) as a perfuming ingredient.

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured:

##STR00001##

or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##

The present invention relates to novel fragrance compounds of general formula (I) which exhibit a Sandalwood-like fragrance and which are derivable from campholenic aldehyde derivates according to general formula (II). Furthermore, the present invention discloses compositions comprising one or more of the inventive fragrance compounds. The invention also relates to the use of such compounds or fragrance compositions comprising one or more of the compounds according to the invention as an odorant or or improving the fixation of a fragrance compound or a fragrance composition. Furthermore, the present invention refers to the use of such compounds or compositions for the preparation of a perfumed products as well as perfumed products as such.

The present invention relates to a novel ligand for forming a ruthenium complex, a ruthenium complex catalyst, a production method therefor and a use thereof. The ligand for forming a ruthenium complex and the ruthenium complex catalyst, according to the present invention, exhibit high catalytic activity, high selectivity, and stability.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:
X-A-Y-L-R  (I)
which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The present invention relates to an acetal compound of the following general formula (1) and an acetal compound of the following general formula (2). The present invention relates to processes for preparing the acetal compound (2), comprising subjecting the acetal compound (1) to a hydrogenation reaction to form the acetal compound (2). The present invention provides a process for preparing 2,3,4,4-tetramethylcyclopentanecarbaldehyde of the following formula (3), comprising subjecting the acetal compound (2) to a hydrolysis reaction to form 2,3,4,4-tetramethylcyclopentanecarbaldehyde (3).

##STR00001##

Described herein is a perfluorinated aminoolefin compound of general formula (I): CFY═CXN(R.sub.f)CF.sub.2R.sub.f′ where: (a) R.sub.f and R.sub.f′ are (i) independently selected from a linear or branched perfluoroalkyl group having 1-8 carbon atoms, optionally comprising at least one catenated O or N atom, or (ii) bonded together to form a perfluorinated ring structure having 4-8 ring carbon atoms, optionally comprising at least one catenated O atom; and (b) X and Y are (i) independently selected from a perfluoroalkyl group having 1-4 carbon atoms, or (ii) bonded together to form a perfluorinated ring structure having 5-6 ring carbon atoms. Such compounds may be used in heat transfer, foam blowing or immersion cooling applications, or as a working fluid in a Rankine cycle, a coating or lubricant, or as a dielectric fluid. Also disclosed herein is a method for making such compounds.